Table 1.
Maximal flow-volume values at baseline, 10 minutes post-treatment and post-5 km time-trial. Data are menas (±SD).
Placebo
SAL800
SAL1600
Baseline
FEV
1
(l)
4.6 (.9)
4.6 (.9)
4.6 (.9)
Predicted FEV
1
(%)
106.0 (13.5)
106.1 (14.5)
106.0 (14.8)
FVC (l)
5.4 (.9)
5.3 (1.0)
5.2 (1.0)
Predicted FVC (%)
103.4 (12.4)
102.0 (13.6)
101.3 (13.4)
FEV
1
%
86.4 (3.4)
87.4 (3.4)
87.6 (3.4)
Post Salbutamol
FEV
1
(l)
4.6 (.9)
4.7 (.9)
4.7 (.9)
FVC (l)
5.3 (.9)
5.3 (.9)
5.2 (1.0)
FEV
1
%
87.1 (3.4)
89.1 (4.1)
*
89.4 (4.1)
*
Post 5 km time-trial
FEV
1
(l)
4.6 (.9)
4.7 (1.0)
4.7 (1.0)
FVC (1)
5.1 (1.0)
5.1 (1.0)
5.1 (1.0)
FEV
1
%
89.9 (5.4)
91.0 (4.7)
92.0 (4.7)
*= significantly greater than PLA.